1. [18F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) response and survival analysis in a phase 1/2 trial of nab-paclitaxel (nab-P) + gemcitabine (gem) for metastatic pancreatic cancer (MPC). (December 2016) Authors: Ramanathan, R.; Von Hoff, D.; Borad, M.; Shiansong Li, J.; McGovern, D.; Renschler, M.; Korn, R. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cholangiocarcinoma with an FGFR2 phenotype: outcomes in patients following surgical resection. (2021) Authors: De la Cruz Ku, G.; Buckarma, E.; Truty, M.; Nagorney, D.; Cleary, S.; Kendrick, M.; Grotz, T.; Borad, M.; Graham, R.; Gores, G.; Smoot, R. Journal: HPB Issue: Volume 23(2021)Supplement 2 Page Start: S492 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor. (October 2022) Authors: Schram, A.; Borad, M.; Sahai, V.; Kamath, S.; Kim, R.; Liao, C.Y.A.; Oh, D.Y.; Ponz-Sarvisé, M.; Yachnin, J.; Shell, S.A.; Cassier, P.; Dotan, E.; Florou, V.; Moreno, V.; Park, J.O.; Tai, D.; Schmidt-Kittler, O.; Ferté, C.; Goyal, L.; Subbiah, V. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S116 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pancreatic cancer models exhibit interferon-independent resistance mechanisms to a Morreton hybrid oncolytic vesiculovirus. (October 2022) Authors: Dumbauld, C.; Gabere, M.; Barro, O.; Nagalo, B.M.; Borad, M. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗